Atlantic Antiplatelet Initiative (AAPI)

The primary goal of the Atlantic Anti-Platelet Initiative (AAPI) was to develop evidence- based guidelines for the acute administration of oral anti-platelet therapy in patients presenting with ACS in Atlantic Canada. Although dual anti-platelet therapy with aspirin and clopidogrel is well established as the regional standard of care, there is currently significant uncertainty in Atlantic Canada about how the novel P2Yi inhibitors prasugrel and ticagrelor should be incorporated into clinical practice. Furthermore, although Canadian Cardiovascular Society anti-platelet guidelines were recently published, they focus on anti-platelet therapy in the outpatient setting and do not address the acute phase of ACS care.